GlassScriptPhysician profile
Mohammad-Ali Doroudchi
NPI 1407316136
$8,068.39
in general payments reported to CMS, 2019-2025
29 companies · $4,771 in 2025
The $4,771 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,184 · 2024: $2,113 · 2025: $4,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,568 · Grant: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,568.39 |
| Grant | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,665.96 | 2023-2025 | |
| Glaxosmithkline, LLC. | $884.10 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $712.45 | 2024-2025 | Tezspire, Fasenra, Breztri |
| Grifols USA, LLC | $637.67 | 2023-2025 | Xembify, Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $601.51 | 2023-2025 | Cuvitru, Cinryze, Takhzyro |
| Pharming Healthcare, INC. | $551.70 | 2023-2025 | Ruconest, Joenja |
| Amgen INC. | $377.97 | 2024-2025 | Tezspire, Actimmune |
| Ars Pharmaceuticals Operations, INC. | $300.12 | 2025 | Neffy |
| Grifols Shared Services North America, INC. | $259.33 | 2024-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $252.80 | 2024-2025 | |
| Blueprint Medicines Corporation | $245.32 | 2024-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $216.23 | 2024-2025 | Dupixent |
| Incyte Corporation | $184.84 | 2025 | Opzelura |
| Biocryst US Sales Co., LLC | $175.59 | 2024-2025 | Orladeyo |
| Leo Pharma INC. | $144.39 | 2025 | Adbry |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $143.55 | 2025 | |
| Pfizer INC. | $107.75 | 2024-2025 | |
| Genentech USA, INC. | $99.16 | 2025 | Xolair |
| Inspire Medical Systems, INC. | $97.32 | 2025 | Inspire |
| Lilly USA, LLC | $82.51 | 2024-2025 | Ebglyss, Taltz |
| Csl Behring | $68.63 | 2025 | Hizentra |
| Galderma Laboratories, L.P. | $48.55 | 2025 | Nemluvio |
| Insmed, INC. | $43.92 | 2025 | Brinsupri, Arikayce |
| Arcutis Biotherapeutics, INC. | $40.40 | 2025 | Zoryve |
| Phadia US INC. | $38.89 | 2024-2025 | Immunocap |
| Ionis Pharmaceuticals, INC. | $31.29 | 2025 | |
| Siemens Medical Solutions USA, INC. | $21.60 | 2025 | Immulite 1000 Immunoassay System |
| Octapharma USA, INC. | $19.53 | 2024 | Octagam Immune Globulin (Human) |
| Cycle Pharmaceuticals INC | $15.31 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad-Ali Doroudchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.